Azithromycin extended release: A review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US

Drugs

Volumn 67, Issue 5, 2007, Pages 773-792

  Harrison, Tracy Swainston ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ATORVASTATIN; AZITHROMYCIN; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CETIRIZINE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DIDANOSINE; DOXYCYCLINE; EFAVIRENZ; FLUCONAZOLE; INDINAVIR; LEVOFLOXACIN; MIDAZOLAM; NELFINAVIR; PENICILLIN DERIVATIVE; PENICILLIN G; PLACEBO; RIFABUTIN; SILDENAFIL; TELITHROMYCIN; THEOPHYLLINE; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ZIDOVUDINE; ZMAX;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHOTOTOXICITY; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SINGLE DRUG DOSE; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; TENDINITIS; TENDON RUPTURE; TREATMENT RESPONSE; UNITED STATES;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DELAYED-ACTION PREPARATIONS; HUMANS; MACROLIDES; SINUSITIS; UNITED STATES;

ANIMALIA; BACTERIA (MICROORGANISMS); CHLAMYDOPHILA PNEUMONIAE; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NEGIBACTERIA; POSIBACTERIA; STREPTOCOCCUS PNEUMONIAE;

EID: 34047240096     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767050-00010     Document Type: Review

References (86)

1. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44 (5): 750-99
2. Gunasekara NS, Barman Balfour JA. Management of community-acquired pneumonia: defining the role of azithromycin. Dis Manage Health Outcomes 1999 Jan; 5: 41-54
3. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996; 51 (3): 483-505
4. Langtry HD, Balfour JA. Azithromycin: a review of its use in paediatric infectious diseases [published erratum appears in Drugs 1998; 56 (2):1046]. Drugs 1998 Aug; 56: 273-97
5. Pfizer Inc. Pfizer's Zithromax receives FDA approval as a once-daily, three-day treatment for acute bacterial sinusitis [online]. Available from URL: http://www.pfizer.com [Accessed 2006 Feb 15]
6. Pfizer Inc. Zmax™ (azithromycin extended release) for oral suspension [online]. Available from URL: http://www.pfizer.com [Accessed 2006 Feb 15]
7. Drehobl MA, De Salvo MC, Lewis DE, et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005 Oct; 128 (4): 2230-7
8. D'Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005 Oct; 49 (10): 4035-41
9. Pfizer Inc. Zithromax® (azithromycin tablets) and (azithromycin for oral suspension) [online]. Available from URL: http://www.pfizer.com [Accessed 2006 Feb 15]
10. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. J Antimicrob Chemother 1999; 43 Suppl. B: 1-11
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document M100-S16 [ISBN 1-56238-588-7]. Wayne (PA): Clinical and Laboratory Standards Institute, 2006 Jan
12. Roblin PM, Kutlin A, Reznik T, et al. In vitro activity of grepafloxacin, levofloxacin, moxifloxacin, trovafloxacin, clarithromycin, and azithromycin against recent clinical isolates of Chlamydia pneumoniae [abstract no. a-94]. 99th General Meeting American Society for Microbiology; 1999 May 30-Jun 3; Chicago (IL), 20
13. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 2003 Dec; 47 (12): 3973-5
14. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46
15. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001; 32 Suppl. 2: S81-93
16. Johnson DM, Sader HS, Fritsche TR, et al. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2003; 47: 373-6
17. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis 2003; 45: 251-9
18. Jenkins SG, Farrell DJ, Patel M, et al. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. J Infect 2005; 51: 355-63
19. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004; 54 Suppl. 1: i7-15
20. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004; 48: 56-65
21. Felmingham D, Reinert RR, Hirakata Y, et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002; 50 Suppl. 1: 25-37
22. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST surveillance program (1998-2002). Clin Infect Dis 2003; 36: 963-70
23. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin Infect Dis 2002; 34 Suppl. 1: S4-16
24. Thornsberry C, Jones ME, Hickey ML, et al. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 1999; 44: 749-59
25. Sahm DF. Resistance issues and community-acquired respiratory infections. Clinical Cornerstone 2003; Suppl. 3: S4-11
26. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003 Jun; 47 (6): 1867-74
27. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003 Jun; 47 (6): 1875-81
28. Roblin PM, Kutlin A, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1997 Sep; 41 (9): 2033-4
29. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998 Jun; 42 (6): 1515-6
30. Roblin PM, Reznik T, Kutlin A, et al. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2003 Mar; 47 (3): 1135-6
31. Kohlhoff SA, Roblin PM, Reznik T, et al. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob Agents Chemother 2004 May; 48 (5): 1885-6
32. Strigl S, Roblin PM, Reznik T, et al. In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae. Antimicrob Agents Chemother 2000 Apr; 44 (4): 1112-3
33. Waites KB, Reddy NB, Crabb DM, et al. Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 2005 Jun; 49 (6): 2541-2
34. Pankuch G, Appelbaum PC. Post-antibiotic effects of LBM415 and other agents against S. pneumoniae and H. influenzae [abstract no. A-1833]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington DC, 32
35. Browne FA, Bozdogan B, Clark C, et al. Antipneumococcal activity of DK-507K, a new quinolone, compared with the activities of 10 other agents. Antimicrob Agents Chemother 2003 Dec; 47 (12): 3815-24
36. Matic V, Kosowska K, Bozdogan B, et al. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. Antimicrob Agents Chemother 2004 Nov; 48 (11): 4103-12
37. Davies TA, Ednie LM, Hoellman DM, et al. Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob Agents Chemother 2000 Jul; 44 (7): 1894-9
38. Credito KL, Lin G., Pankuch GA, et al. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob Agents Chemother 2001 Jan; 45 (1): 67-72
39. Bergman KL, Olsen KM, Peddicord TE, et al. Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of Haemophilus influenzae and Streptococcus pneumoniae. Antimicrob Agents Chemother 1999 May; 43: 1291-3
40. Pankuch G, Lin G, Appelbaum PC. Time-kill activities of ceftobiprole and eight other agents against H. influenzae and M. catarrhalis [abstract no. E-305]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington DC, 157
41. Kosowska K, Credito K, Pankuch GA, et al. Activities of two novel macrolides, GW 773546 and GW 708408 compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. Antimicrob Agents Chemother 2004 Nov; 48 (11): 4113-9
42. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 2005 Jun; 11 (6): 802-7
43. Garau J. The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg? Respir Med 2001 Jun; 95 Suppl. A: S5-11
44. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002 Sep 1; 35 (5): 556-64
45. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy [letter]. Chest 2000 Dec; 118 (6): 1839-40
46. Kelley MA, Weber DJ, Gilligan P, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000 Oct; 31 (4): 1008-11
47. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000 Aug; 31 (2): 613-5
48. Peric M, Bozdogan B, Jacobs MR, et al. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 2003 Mar; 47 (3): 1017-22
49. Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 2004 Aug 2; 117 Suppl. 3A: 3-15S
50. Farrell DJ, Jenkins SG, Brown SD, et al. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 2005 Jun; 11 (6): 851-8
51. Farrell DJ, Jenkins SG. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. J Antimicrob Chemother 2004 Aug; 54 Suppl. 1: i17-22
52. Farrell DJ, Jenkins SG, Patel M, et al. Antimicrobial resistance patterns among Streptococcus pneumoniae isolated from elderly patients: data from the PROTEKT U.S. study years 1-4 [abstract no. C2-231]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington DC, 91
53. Wierzbowski AK, Swedlow D, Nichol K, et al. Molecular characterization of macrolide resistant Streptococcus pneumoniae isolates containing both erm(B) and mef(A) genes isolated during 1997-2004 Canadian Respiratory Organism Susceptibility Study (CROSS) [abstract no. C2-235]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington DC, 92
54. Pankuch GA, Jueneman SA, Davies TA, et al. In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 1998 Nov; 42 (11): 2914-8
55. Davies TA, Dewasse BE, Jacobs MR, et al. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000 Feb; 44 (2): 414-7
56. Sahm DF, Weaver MK, Flamm RK, et al. Rates of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States: results from the TRUST 7 (2002-2003) Surveillance Study [abstract no. 201 plus poster]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 9-12 Oct; San Diego (CA), 63
57. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 2004; 50 Suppl. 1: 3-10
58. Murray JJ, Emparanza P, Lesinskas E, et al. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol Head Neck Surg 2005 Aug; 133 (2): 194-200
59. Rothermel CD. Single-dose azithromycin for acute otitis media: a pharmacokinetic/pharmacodynamic rationale. Curr Ther Res Clin Exp 2003; 64 Suppl. A: A4-15
60. Craig WA, Kiem S, Andes DR, et al. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin [abstract no. A-1264]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA), 14
61. Girard D, Finegan SM, Dunne MW, et al. Enhanced efficacy of single-dose versus multi-dose azithromycin regiments in preclinical infection models. J Antimicrob Chemother 2005; 56: 365-71
62. Abbott Laboratories. Biaxin® Filmtab® (clarithromycin tablets, USP) Biaxin® XL Filmtab® (clarithromycin extended-release tablets) Biaxin® Granules (clarithromycin for oral suspension, USP) [online]. Available from URL: http://www.rxabbott.com [Accessed 2006 Feb 14]
63. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis [published erratum appears in Otolaryngol Head Neck Surg 2004; 130 (6): 794-6]. Otolaryngol Head Neck Surg 2004 Jan; 130 (1 Suppl.): 1-45
64. Retsema JA. Susceptibility and resistance emergence studies with macrolides. Int J Antimicrob Agents 1999 Mar; 11 Suppl. 1: S15-21
65. Matute AJ, Schurink CA, Krijnen RM, et al. Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers. Eur J Clin Microbiol Infect Dis 2002 Jun; 21 (6): 427-31
66. Kamicker BJ, Bertsche CD, Medina IA. In rodent models a single dose of azithromycin was more effective than dosing split over 3 or 5 days [poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington DC
67. Liu P, Allaudeen H, Chandra R, et al. Serum and white blood cell (WBC) pharmacokinetics (PK) of a novel, single-dose azithromycin (AZ) microsphere formulation [abstract no. A-23]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington DC, 5
68. Danesi R, Lucchi M, Pasqualetti G, et al. Single-dose azithromycin microspheres (AZ-M) achieves improved lung pharmacokinetics versus azithromycin tablets (AZ-IR) [poster #A62]. 102nd International Conference of the American Thoracic Society; 2006 19-24 May; San Diego (CA), A150
69. Breen J, Chandra R, Herbig S, et al. Zmax: A novel microsphere-based azithromycin dosage form [poster]. American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 2005 Nov 6-10; Nashville (TN)
70. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50
71. Marple BF. Editorial commentary: Dilemma in trial design: do current study designs adequately evaluate effectiveness antibiotic in ABRS? Otolaryngol Head Neck Surg 2005 Aug; 133 (2): 200-1
72. Piccirillo JF. Clinical practice. Acute bacterial sinusitis. N Engl J Med 2004 Aug 26; 351 (9): 902-10
73. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001 Jun; 163 (7): 1730-54
74. National Institute of Allergy and Infectious Diseases. Sinusitis [online]. Available from URL: http://www.niaid.nih.gov/factsheets/sinusitis.htm [Accessed 2006 Feb 13]
75. Thibodeau KP, Viera AJ. Atypical pathogens and challenges in community-acquired pneumonia. Am Fam Physician 2004 Apr 1; 69 (7): 1699-706
76. National Institute of Allergy and Infectious Diseases. Pneumococcal pneumonia [online]. Available from URL: http://www.niaid.nih.gov/factsheets/ pneumonia.htm [Accessed 2006 Feb 13]
77. Niederman MS. Review of treatment guidelines for community-acquired pneumonia. Am J Med 2004 Aug 2; 117 Suppl. 3A: 51-7S
78. Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med 2001; 134: 498-505
79. Snow V, Mottur-Pilson C, Hickner JM. Principles of appropriate antibiotic use for acute sinusitis in adults. Ann Intern Med 2001; 134: 495-7
80. Lutfiyya MN, Henley E, Chang LF, et al. Diagnosis and treatment of community-acquired pneumonia. Am Fam Physician 2006; 73: 442-50
81. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003 Dec 1; 37 (11): 1405-33
82. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001 Sep 15; 33 Suppl. 3: S187-92
83. Edelstein PH. Predicting the emergence of antimicrobial resistance [letter]. Clin Infect Dis 2002 May 15; 34 (10): 1418; author reply 1418-9
84. Pfizer Inc. Pfizer's single-dose antibiotic Zmax receives FDA approval [online]. Available from URL: http://www.zmax-info.com [Accessed 2006 Mar 30]
85. Ortho-McNeil Pharmaceutical Inc. Levaquin® (levofloxacin) tablets Levaquin® (levofloxaxin) oral solution Levaquin® (levlofloxacin) injection Levaquin® (levafloxacin in 5% dextrose) injection Prescribing Information [online]. Available from URL: www.levaquin.com [Accessed 2006 Jun 8]
86. Sorensen SV, Baker TM, Mallya UG, et al. Pharmacoeconomic evaluation of single dose azithromycin extended release for the treatment of community-acquired pneumonia [abstract no. CE1]. Value Health 2006 May 30; 9 (3): 7